Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.

Wirta, David L; Korenfeld, Michael S; Foster, Shane; Smyth-Medina, Robert; Bacharach, Jason; Kannarr, Shane R; Jaros, Mark J; Slonim, Charles B

Wirta, David L; Korenfeld, Michael S; Foster, Shane; Smyth-Medina, Robert; Bacharach, Jason; Kannarr, Shane R; Jaros, Mark J; Slonim, Charles B.

Afiliação

Wirta DL; Aesthetic Eye Care Institute & Eye Research Foundation, Newport Beach, CA, USA.
Korenfeld MS; Comprehensive Eye Care, Ltd., Washington, MO, USA.
Foster S; Athens Eye Care, Athens, OH, USA.
Smyth-Medina R; North Valley Eye Medical Group, Mission Hills, CA, USA.
Bacharach J; North Bay Eye Associates, Petaluma, CA, USA.
Kannarr SR; Kannarr Eye Care, Pittsburg, KS, USA.
Jaros MJ; Summit Analytical, Denver, CO, USA.
Slonim CB; Department of Ophthalmology, University of South Florida Morsani College of Medicine, Tampa, FL, USA.

Clin Ophthalmol ; 15: 4035-4048, 2021.

Article em En | MEDLINE | ID: mdl-34675472

Palavras-chave

Müller's muscle; adrenergic agonist; adverse event; eye drop; intraocular pressure; pupil; topical

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article